Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.
Identifieur interne : 001319 ( PubMed/Corpus ); précédent : 001318; suivant : 001320Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.
Auteurs : B P Bejjani ; D. Gervais ; I. Arnulf ; S. Papadopoulos ; S. Demeret ; A M Bonnet ; P. Cornu ; P. Damier ; Y. AgidSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 2000.
English descriptors
- KwdEn :
- Adult, Antiparkinson Agents (therapeutic use), Electric Stimulation Therapy, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Motor Skills, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Severity of Illness Index, Subthalamic Nucleus (physiology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- physiology : Subthalamic Nucleus.
- physiopathology : Parkinson Disease.
- Adult, Electric Stimulation Therapy, Female, Humans, Male, Middle Aged, Motor Skills, Severity of Illness Index, Treatment Outcome.
Abstract
To assess the effects of high frequency stimulation of the subthalamic nucleus (STN) on axial symptoms occurring in advanced stages of Parkinson's disease (PD).
PubMed: 10766889
Links to Exploration step
pubmed:10766889Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.</title><author><name sortKey="Bejjani, B P" sort="Bejjani, B P" uniqKey="Bejjani B" first="B P" last="Bejjani">B P Bejjani</name><affiliation><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and INSERM U289, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gervais, D" sort="Gervais, D" uniqKey="Gervais D" first="D" last="Gervais">D. Gervais</name></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Papadopoulos, S" sort="Papadopoulos, S" uniqKey="Papadopoulos S" first="S" last="Papadopoulos">S. Papadopoulos</name></author><author><name sortKey="Demeret, S" sort="Demeret, S" uniqKey="Demeret S" first="S" last="Demeret">S. Demeret</name></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name></author><author><name sortKey="Cornu, P" sort="Cornu, P" uniqKey="Cornu P" first="P" last="Cornu">P. Cornu</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10766889</idno><idno type="pmid">10766889</idno><idno type="wicri:Area/PubMed/Corpus">001319</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001319</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.</title><author><name sortKey="Bejjani, B P" sort="Bejjani, B P" uniqKey="Bejjani B" first="B P" last="Bejjani">B P Bejjani</name><affiliation><nlm:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and INSERM U289, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gervais, D" sort="Gervais, D" uniqKey="Gervais D" first="D" last="Gervais">D. Gervais</name></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I" last="Arnulf">I. Arnulf</name></author><author><name sortKey="Papadopoulos, S" sort="Papadopoulos, S" uniqKey="Papadopoulos S" first="S" last="Papadopoulos">S. Papadopoulos</name></author><author><name sortKey="Demeret, S" sort="Demeret, S" uniqKey="Demeret S" first="S" last="Demeret">S. Demeret</name></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A M" last="Bonnet">A M Bonnet</name></author><author><name sortKey="Cornu, P" sort="Cornu, P" uniqKey="Cornu P" first="P" last="Cornu">P. Cornu</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiparkinson Agents (therapeutic use)</term><term>Electric Stimulation Therapy</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Motor Skills</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Severity of Illness Index</term><term>Subthalamic Nucleus (physiology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Electric Stimulation Therapy</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor Skills</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To assess the effects of high frequency stimulation of the subthalamic nucleus (STN) on axial symptoms occurring in advanced stages of Parkinson's disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10766889</PMID><DateCreated><Year>2000</Year><Month>05</Month><Day>30</Day></DateCreated><DateCompleted><Year>2000</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.</ArticleTitle><Pagination><MedlinePgn>595-600</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effects of high frequency stimulation of the subthalamic nucleus (STN) on axial symptoms occurring in advanced stages of Parkinson's disease (PD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The efficacy of STN stimulation on total motor disability score (unified Parkinson's disease rating scale (UPDRS) part III) were evaluated in 10 patients with severe Parkinson's disease. The subscores were then studied separately for limb akinesia, rigidity, and tremor, which are known to respond to levodopa, and axial signs, including speech, neck rigidity, rising from a chair, posture, gait, and postural stability, which are known to respond less well to levodopa. Patients were clinically assessed in the "off" and "on" drug condition during a levodopa challenge test performed before surgical implantation of stimulation electrodes and repeated 6 months after surgery under continuous STN stimulation. A complementary score for axial symptoms from the "activities of daily living" (ADL)-that is, speech, swallowing, turning in bed, falling, walking, and freezing-was obtained from each patient's questionnaire (UPDRS, part II).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Improvements in total motor disability score (62%), limb signs (62%), and axial signs (72%) obtained with STN stimulation were statistically comparable with those obtained with levodopa during the preoperative challenge (68%, 69%, and 59%, respectively). When levodopa and STN stimulation were combined there was a further improvement in total motor disability (80%) compared with preoperative levodopa administration. This consisted largely of an additional improvement in axial signs (84%) mainly for posture and postural stability, no further improvement in levodopa responsive signs being found. Axial symptoms from the ADL showed similar additional improvement when levodopa and STN stimulation were combined.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that bilateral STN stimulation improves most axial features of Parkinson's disease and that a synergistic effect can be obtained when stimulation is used in conjunction with levodopa treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bejjani</LastName><ForeName>B P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and INSERM U289, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Arnulf</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Demeret</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Cornu</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1967 May;17(5):427-42</RefSource><PMID Version="1">6067254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Oct 15;339(16):1105-11</RefSource><PMID Version="1">9770557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1976 May;26(5):399-404</RefSource><PMID Version="1">944392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1986 Mar;396(1):47-63</RefSource><PMID Version="1">2871904</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1987;45:1-18</RefSource><PMID Version="1">3825687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1987 Sep;37(9):1539-42</RefSource><PMID Version="1">3627454</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1986;1(3):187-92</RefSource><PMID Version="1">3504244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1989;4 Suppl 1:S126-44</RefSource><PMID Version="1">2566912</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comp Neurol. 1990 Apr 8;294(2):306-23</RefSource><PMID Version="1">2332533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1991 Jun 1;337(8753):1321-4</RefSource><PMID Version="1">1674304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1992 Feb;42(2):333-9</RefSource><PMID Version="1">1736161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1994 May;60(1):125-32</RefSource><PMID Version="1">8052406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comp Neurol. 1994 Jun 8;344(2):190-209</RefSource><PMID Version="1">7915726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stereotact Funct Neurosurg. 1994;62(1-4):76-84</RefSource><PMID Version="1">7631092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1996 Dec;61(6):645-8</RefSource><PMID Version="1">8971118</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1093-107</RefSource><PMID Version="1">9194437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Jul;49(1):249-53</RefSource><PMID Version="1">9222199</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1997 Oct 9;337(15):1036-42</RefSource><PMID Version="1">9321531</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1997 Dec;49(6):1564-9</RefSource><PMID Version="1">9409347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1997 Dec 12;239(1):13-6</RefSource><PMID Version="1">9547160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1998 Sep;51(3):850-5</RefSource><PMID Version="1">9748038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Med Interne (Paris). 1972 Apr;123(4):349-56</RefSource><PMID Version="1">5077039</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004599" MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="Y">Motor Skills</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1736917</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10766889</ArticleId><ArticleId IdType="pmc">PMC1736917</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001319 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001319 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:10766889
|texte= Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10766889" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |